Top-line Analysis of CVac Phase 2 Trial

0.0250 (0.00%)View full PRR report with
  1. 42.0k
    Posts

    PRR - Top-line Analysis of CVac Phase 2 Trial

    SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) (Prima, the Company) today announced top-line analysis of the CAN-003 phase 2 study of CVac for treatment of epithelial ovarian cancer patients in first or second remission.

Your browser is too old for TopStocks and not secure. Please update your browser